{"acquisitions":[],"changes":[],"country":"US","description":"Syremis Therapeutics is a Tel Aviv clinical-stage biotech developing oral small molecules for schizophrenia, depression, and other psychiatric disorders. Lead drug ST-905, a once-daily M1/M4 muscarinic agonist, is in Phase 1. Co-founded by the team behind Karuna's Cobenfy and launched with a $165M Series A.","domain":"syremisrx.com","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":42.358834,"lng":-71.05783,"location":"Boston MA","multiples":[],"name":"Syremis Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":165000000,"connectionsAmong":[],"currency":"USD","date":"2025-08-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"syremisrx-com-2025-08-01-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"syremisrx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"syremisrx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://syremisrx.com"},{"fact":"description","publisher":"syremisrx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://syremisrx.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":165000000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}